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Abstract
While HIV-1-specific cellular immunity is thought to be critical for the suppression of viral replication, the correlates of
protection have not yet been determined. Rhesus macaques (RM) are an important animal model for the study and
development of vaccines against HIV/AIDS. Our laboratory has helped to develop and study DNA-based vaccines in which
recent technological advances, including genetic optimization and in vivo electroporation (EP), have helped to dramatically
boost their immunogenicity. In this study, RMs were immunized with a DNA vaccine including individual plasmids encoding
SIV gag, env, and pol alone, or in combination with a molecular adjuvant, plasmid DNA expressing the chemokine ligand 5
(RANTES), followed by EP. Along with standard immunological assays, flow-based activation analysis without ex vivo
restimulation and high-throughput gene expression analysis was performed. Strong cellular immunity was induced by
vaccination which was supported by all assays including PBMC microarray analysis that identified the up-regulation of 563
gene sequences including those involved in interferon signaling. Furthermore, 699 gene sequences were differentially
regulated in these groups at peak viremia following SIVmac251 challenge. We observed that the RANTES-adjuvanted
animals were significantly better at suppressing viral replication during chronic infection and exhibited a distinct pattern of
gene expression which included immune cell-trafficking and cell cycle genes. Furthermore, a greater percentage of vaccine-
induced central memory CD8+ T-cells capable of an activated phenotype were detected in these animals as measured by
activation analysis. Thus, co-immunization with the RANTES molecular adjuvant followed by EP led to the generation of
cellular immunity that was transcriptionally distinct and had a greater protective efficacy than its DNA alone counterpart.
Furthermore, activation analysis and high-throughput gene expression data may provide better insight into mechanisms of
viral control than may be observed using standard immunological assays.
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Introduction
The development of an effective HIV vaccine has proven to be
a significant challenge and the exact nature of a protective
immune profile remains elusive. Importantly, the RV144 trial is
the first study that has demonstrated any sort of efficacy [1]. It was
a randomized trial of the ‘‘prime-boost’’ combination of ALVAC
HIV (prime) and AIDSVAX B/E (boost) versus placebo
conducted in more than 16,000 HIV-negative volunteers in
Thailand. A relative reduction in viral infection (31.1%) was
observed in vaccinated subjects with an absolute difference of
0?28%. Furthermore, binding Abs were observed in most
vaccinated subjects suggesting their importance in protection from
infection [1]. However, the Ab response alone is not likely the only
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e19681
20contributor to efficacy and a number of studies have indicated that
a cellular immunity also contributes to protection against HIV
infection in humans and SIV infection in RMs [2,3]; high CD4
+
T-cell and CD8
+ T-cell gamma interferon (IFN- c) responses are
associated with better viral control during chronic SIV infection
[4]. In human studies, the CD8
+ T-cell response and the HIV-1
viral load during primary infection have been shown to be
inversely related [5,6,7,8,9,10]. Studies of chronic infection suggest
that non-progressors maintain HIV-specific CD8
+ T-cell prolifer-
ation [11] and polyfunctional HIV-specific CD8
+ T-cell responses
[12]. Finally, in vivo depletion of CD8
+ T-cells in SIV- or
SHIV89.6p-infected RMs implicates the importance of T-cells in
the control of viral replication during both acute [13] and chronic
[14] infection. More recently, impairment of CD4
+ and CD8
+ cell
function through the up-regulation of inhibitory T-cell surface
markers has been observed with disease progression during HIV-1
and SIV infection [15,16,17,18,19]. One of the goals of the
current study was to develop an SIV DNA vaccine that induces
strong SIV-specific cellular immune responses by optimizing its
delivery using in vivo electroporation (EP) and its expression using
co-delivery of a plasmid molecular adjuvant encoding the
chemokine ligand 5 (RANTES).
RANTES (or Regulated upon Activation, Normal T-cell
Expressed, and Secreted), member of the CC-chemokine family
and similar to other CCR5 ligand-macrophage inflammatory
proteins 1a (MIP-1a) and 1b (MIP-1b), can inhibit the entry of
HIV type 1 (HIV-1) strains that use CCR5 as an entry co-receptor
with CD4 (R5 strains) [20,21]. These chemokines inhibit entry of
the virus at binding sites located on the same receptor, leading to
suppression of CCR5-tropic (R5-tropic) HIV-1 infections [22]. In
addition, RANTES has been demonstrated to be predominantly
associated with T helper type-1 (Th1) responses [23,24,25]. An
immune response polarized towards a Th1 phenotype is associated
with a reduced viral load and non-progression of disease during
HIV-1 infection [26]. Furthermore, RANTES has been found to
enhance cellular immune responses resulting in a more effective
immune-modulating effect against HIV-1-related viruses in rodent
and monkey models [27,28,29,30]. Thus, based on these previous
studies describing its immunogenicity in relation to HIV,
RANTES was selected as a molecular adjuvant in the present
study.
Since standard immunological assays measuring the magnitude
and functional capacity of vaccine-specific T cell responses has
provided little correlation with protection from HIV disease [31],
we used several non-standard assays to ascertain possible
mechanisms of viral suppression. Firstly, we employed flow-based
activation analysis in the absence of ex vivo restimulation which has
been shown to correlate T cell activation with vaccine-induced
immune responses and is highly specific with minimal bystander
effects [32]. Next, to examine vaccine-induced genetic signatures
we used microarrays which have provided during both HIV-1 and
SIV infection numerous mechanistic insights into pathogenesis
including the timing of innate gene expression, interferon
stimulated genes, the regulation of apoptosis in different cell
types, and many others [33,34,35,36]. However, the application of
high-throughput global gene expression analysis to HIV and SIV
vaccine studies has generally been limited in number and these
studies did not specifically examine expression in RM suppressors
of SIV replication. Thus, the acquisition of high-throughput data
in HIV and SIV vaccine studies will allow for sensitive
interrogation of adaptive immune pathways previously theorized
to influence efficacy and provide information about responses,
such as innate responses, that have not been as well-characterized
with regard to vaccine efficacy.
We demonstrate herein that a SIV DNA vaccine can induce
strong cellular immunity and suppress SIV viral replication when
administered in conjunction with a plasmid molecular adjuvant
expressing RANTES. Vaccine-specific immune responses were
assessed using standard immunological assays including both
ELISpot and flow cytometry, but no direct correlation between
immunity and viral load was found. We therefore employed non-
standard immunological techniques including activation analysis
in the absence of ex vivo restimulation [32] and genetic analysis to
better analyze the data. While DNA vaccination alone induced a
greater amount of SIV-specific effectors as measured by standard
immunological assays, DNA vaccination adjuvanted by RANTES
as measured by activation analysis generated a greater percentage
of central memory CD8+ T-cells capable of an activated
phenotype following the final immunization. Microarrays were
used to examine the expression of 20,217 gene sequences in
PBMCs from vaccinated animals that were stimulated in vitro with
SIVpol peptides; 563 gene sequences distinguished the vaccine
groups at eight months following immunization and 699 gene
sequences distinguished them post-challenge at peak viremia. We
found that vaccination was associated with an enhanced Th1 gene
expression response including interferon signaling and chemokine
response to SIVpol at both pre- and post- challenge, which was
consistent with the standard immunological assays. Furthermore,
that vaccination caused an up-regulation in the transcription of
immune response pathways that included cytolysis-related genes at
8 months post-vaccination. Interestingly, we observed that a
decrease in cell death-related genes correlated with vaccination at
peak viremia. Lastly, a unique signature of genes whose expression
distinguished the RANTES group was observed. These RANTES-
specific gene expression patterns may suggest a long-term
reprogramming of the immune response to SIVpol that is unique
to the animals that received this adjuvant and could offer insight
into the enhanced SIV suppression observed post-challenge.
Materials and Methods
Animals and infection
Rhesus macaques (Macaca mulatta) were housed at BIOQ-
UAL, Inc. (Rockville, MD), in accordance with the standards of
the American Association for Accreditation of Laboratory Animal
Care. The protocol was approved by the BIOQUAL’s Institu-
tional Animal care and Use Committee under OLAW Assurance
Number of A-3086-01. Bioqual is IAAALAC accredited and
procedures were in accordance with the recommendations of the
Weatherall report. The University of Pennsylvania Institutional
Animal Care and Use Committee (IACUC) reviewed and
approved all procedures carried out by BIOQUAL. Animals were
allowed to acclimate for at least 30 days in quarantine prior to any
experimentation. All animals received environmental enrichment
throughout this study. All experimental procedures were per-
formed under ketamine anesthesia and all efforts were made to
minimize pain and suffering.
Animals were challenged eight months following the fourth
immunization with 25 monkey infectious doses (MID) of SIVmac251
by the intrarectal route. Viral stocks were provided by Advanced
BioSciences Laboratories, Inc (ABL Inc.; Kensington, MD) and
titered by BIOQUAL, Inc. Plasma viral load was determined by
quantitative Nucleic Acid Sequence Based Amplification (NASBA)
assay performed by Advanced BioSciences Laboratories, Inc (ABL,
Inc.; Kensington, MD) as previously described [37]. CD4+ T-cell
numbers were also measured by ABL and titered by Bioqual Inc.
(Rockville, MD).
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The DNA plasmids used in this study expressed the modified
RM proteins for SIV gag (pSIVgag), pol (pSIVpol), or env
(pSIVenv). Consensus sequences were generated with several
modifications as follows. Expression was enhanced using a human
IgE leader peptide [38], SIV env V1 and V2 regions were
shortened by removing N-linked glycosylation sites, and the
cytoplasmic tail was truncated to prevent envelope recycling. For
SIV pol, three mutations were introduced to deactivate the
protease, reverse transcriptase, and RNase H. The resulting
optimized SIV DNA immunogens were codon- and RNA-
optimized, synthesized, and cloned into the pVAX1 expression
vector to create optimized expression constructs. Constructs were
amplified and purified by Aldevron (Fargo, ND) and then
formulated in 0.15 M citrate buffer of pH 6.7 with 0.25%
bupivicaine in water.
The DNA alone group consisted of six RMs that were
immunized at weeks 0, 8, 12 and 24 with a mixture of 1.5 mg
each of pSIVgag, pSIVpol, and pSIVenv. The RANTES-
adjuvanted group consisted of six RMs that received a mixture
of 1.5 mg each of SIVgag, SIVenv, SIVpol and RANTES at
weeks 0, 8, 12 and for the 4th immunization at week 24, received
only DNA but no RANTES adjuvant. Lastly, a third group of six
RMs were used as the negative control group (Naı ¨ve) and
immunized with saline (Table 1). For each immunization, plasmid
DNA was delivered into a single injection site in the quadriceps
muscle followed by in vivo EP. All EP procedures were performed
using the CELLECTRA
TM device (Inovio Biomedical Corpora-
tion, The Woodlands, TX) at a constant current consisting of 3
pulses at 0.5 Amps, with each pulse being 52 ms in length and
separated by 1 second intervals. This software-controlled device
Figure 1. Immunization induces robust SIV-specific responses. PBMCs were isolated two weeks after each immunization and SIV-specific IFN-
c responses were assessed by standard ELISpot. Average levels of IFN-c producing cells for the Control (A), DNA (B), and DNA+RANTES (C) groups
after stimulation with SIV peptides (gag, env, or pol) are displayed. (D) Average responses per vaccine group for the individual Ags following each
successive immunization. Error bars represent SD.
doi:10.1371/journal.pone.0019681.g001
Table 1. Immunization schedule.
Immunization Control group DNA group DNA+RANTES group
Week 0 Control SIV gag SIV gag
SIV env SIV env+RANTES
SIV pol SIV pol
Week 8 Control SIV gag SIV gag
SIV env SIV env+RANTES
SIV pol SIV pol
Week 12 Control SIV gag SIV gag
SIV env SIV env+RANTES
SIV pol SIV pol
Week 20 Control SIV gag SIV gag
SIV env SIV env
SIV pol SIV pol
doi:10.1371/journal.pone.0019681.t001
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plasmid delivery and generation of constant current square wave
pulses, thus eliminating the risk of delivery outside the muscle
tissue and potential plasmid loss [39,40].
PBMC isolation
For the isolation of PBMCs, blood was collected in EDTA
tubes, shipped overnight, transferred to conical tubes, and
centrifuged at 2,000 rpm to pellet cells. Plasma was separated
from cells and replaced with an equivalent volume of Hanks’
Balanced Salt Solution (HBSS; Invitrogen, Grand Island, NY).
PBMC were isolated by standard Ficoll-hypaque centrifugation
and residual red blood cells were lysed using ammonium chloride-
potassium (ACK) Lysing Buffer (Lonza, Walkersville, MD). Cells
were washed twice with HBSS and then resuspended in complete
culture medium (RPMI 1640 with 2 mM/L L-glutamine,
100 IU/ml each of penicillin and streptomycin, 55 mm/L b-
mercaptoethanol, and 10% heat-inactivated fetal bovine serum
(FBS)). Viable cells were counted using a 0.4% (w/v) Trypan Blue
Solution (Mediatech Inc., Herndon, VA).
IFN-c ELISpot assay
RM ELISpot was performed as previously described [41]. Briefly,
ELISpot assays using IFN-c reagents (MabTech, Sweden) and
nitrocellulose plates (Millipore,B i l l e r i c a ,M A )w e r ep e r f o r m e d
according to the manufacturer’s instructions. Ninety-six well Multi-
Screen-IP plates with hydrophobic PVDF filters (0.45 mm) (Millipore,
Billerica, MA) were coated with IFN-ccapture antibody and incubated
o v e r n i g h ta t4 uC. After washing with sterile PBS, the wells were
blocked with complete culture medium for at least 30 min at room
Figure 2. Proliferative capacity of SIV-specific T-cells in vaccinated animals. PBMCs from DNA-vaccinated RMs were isolated 4 weeks
following the final immunization and analyzed for proliferative capacity. (A) Proliferation by CD4+ (top) and CD8+ (bottom) T-cells from one
representative animal in the DNA-vaccinated group that were incubated for 5 days in the presence of medium alone, SIV peptides (gag, env, or pol),
or ConA. Pseudo-color dot plots are gated on live CD3+ cells and T-cell gates are displayed with numbers representing total percent of CFSEdim T-
cells. (B) T-cell data for each peptide (medium alone values subtracted) is enumerated per immunization group and shown for CD4+ and CD8+ T-cells.
Error bars represent SD; *P,0.05 per the unpaired t test.
doi:10.1371/journal.pone.0019681.g002
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amino acids; NIH AIDS Research & Reference Reagent Program,
Germantown, MD) were diluted 1:200 in culture medium and 100 ml
was transferred into triplicate wells. Peptide matrices were made as
previously described [42]. Cells in culture media were added to the
wells at a concentration of 200,000 cells per well and the plate was
incubated for 18–24 h at 37uC, 5% CO2.A f t e rw a s h i n gw i t hs t e r i l e
PBS, biotinylated antibody (1 mg/ml) in PBS with 0.5% FBS was
added and incubated for 2 h at room temperature. Wells were washed
with sterile PBS and streptavidin-ALP was added at a concentration of
1 ng/ml in PBS with 0.5% PCS and incubated for 1 h at room
temperature. Plates were washed again with sterile PBS and BCIP/
N B T( S i g m a ,S t .L o u i s ,M O )w a sa d d e da n di n c u b a t e du n t i ls p o t s
appeared. Reactions were stopped using tap water and plates were left
overnight at room temperature to dry. A positive response was defined
as greater than 50 spot forming cells (SFC) per million PBMCs and two
times above background and enumerated using an ImmunoSpotH
Analyzer and ImmunospotH Version 3.0 software (Cellular Technol-
ogy Ltd., Shaker Heights, OH), in the negative control wells from the
wells containing peptides.
T-cell proliferation and flow cytometry
Fresh PBMCs were incubated with CFSE (5 mM) for 8 min at
37uC. Cells were washed and incubated with medium alone
(negative control), peptides (SIV239gag peptide mix, SIV239env
peptide mix, SIV239pol peptide mix) at a concentration of 5 ug/
mL, or Concanavalin A (ConA; positive control) for 5 days at
37uC in 96-well plates. Cultures with medium alone were used to
determine the background proliferative responses. PBMCs were
immunostained with the following mAbs: anti-CD3 APC-Cy7
(BD-Pharmingen, San Diego, CA), anti-CD4 PerCP-Cy5.5 (BD-
Pharmingen, San Diego, CA), anti-CD8 APC or AmCyan (BD-
Pharmingen, San Diego, CA). Stained and fixed cells were
acquired on an LSRI instrument using CellQuest software (BD
Biosciences) and analyzed with FlowJo software (Tree Star,
Ashland, OR). The level of CXCR3 was assessed using antibodies
specific for CXCR3, CCR7, IFN-c, CD3, CD8, and CD4 (BD-
Pharmingen, San Diego, CA).
Cellular activation assay
Vaccine-induced cellular activation was examined using a flow-
basedactivationassay.Briefly,frozenPBMCsamplescollectedbefore
the first immunization (pre-bleed) and after the fourth (post-
immunization) were thawed, rested overnight in complete medium,
stained, and then analyzed by flow cytometry. The overall change
in total T-cell activation on a per animal basis was determined in the
absence of ex vivo stimulation by the difference in T-cell surface
expression of HLA-DR between the pre-bleed and the post-
immunization samples. Immunostaining of PBMCs was performed
using LIVE/DEADH Fixable Violet Dead Cell Stain Kit for 20 min
at RT (Invitrogen) per the manufacturer’s instructions and then
washed and stained for 30 min at 4uC with PBS containing 1% FBS
(1% PBS) including the following Abs: QdotH 655-conjugated anti-
CD4 (clone 19Thy-5D7; NIH), QdotH 605-CD45RA (clone MEM-
56; Invitrogen), Alexa FluorH700-conjugated HLA-DR (clone L243;
BioLegend, San Diego, CA), AmCyan-CD8 (clone SK1; BD) and
PE-Cy
TM5-CD95 (clone DX2; BD). Next, after three washes with
PBS, intracellular staining was performed using the BD Cytofix/
Cytoperm
TM kit and APC-Cy
TM7-CD3 (clone SP34-2; BD) in
perm/wash buffer for 30 min at 4uC. Following staining, cells were
washed and fixed with 1% paraformaldehyde. Data was collected
using a LSRII flow cytometer (BD) and analyzed using FlowJo
software (Tree Star, Ashland, OR).
RNA extraction, synthesis of cRNA probes, and
microarray hybridization
Total RNA for microarray analysis was isolated according to
the manufacturer’s protocol and further purified with an RNeasy
Mini Kit (catalog no. 74104; Qiagen). Microarray analysis was
performed on RNA from PBMCs taken from the animals at eight
Figure 3. RANTES increases central memory CD8+ T formation
during DNA vaccination. PBMCs isolated before the first immuniza-
tion (Pre-bleed) and 2 weeks following the fourth (Post-imm.) were
stained without ex vivo stimulation and analyzed by flow cytometry. (A)
Strategy showing gating of total lymphocytes, live CD3+ cells, CD4+
and CD8+ T-cells, and activated cells (HLA-DR+CD95+). (B) Vaccine-
induced activation from before (Pre-bleed) and after immunization
(Post-imm.) are shown as dot plots with total CD8+ cells (red) overlayed
by activated ones (blue) as a function of CD28 and CD45RA. The
average percentage of activation per group of animals (Post-imm. – Pre-
bleed) is displayed to the right for total CD8+ (red bars) and CD4+ (blue
bars) T-cells. (C) Activated memory T-cell subsets were determined by
gating as a function of CD28 and CD45RA, which differentiate naı ¨ve (N;
CD28+CD45RA+), effectors/terminally differentiated effectors (TE;
CD282CD45RA+), central memory (TEM; CD28+CD45RA2) and effector
memory (TEM; CD282CD45RA2). The average percentage of activated
cells for each phenotype is enumerated on right for DNA (white bars)
versus DNA+RANTES (black bars) vaccinated animals. Graphs are
pseudo-color and contour plots with outliers shown and data are from
a representative animal. Error bars represent SD; *P,0.05, and
**P,0.005 per the unpaired t test.
doi:10.1371/journal.pone.0019681.g003
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PBMC samples were isolated and stimulated for 24 h in vitro with
either a SIV pol peptide pool or R10 control. This method of
stimulation was used to elicit gene expression reflecting specific
memory response to the SIV pol antigen. Microarray analysis was
performed using Agilent RM 4644 K microarrays using the
manufacturer’s one-color analysis protocol. Microarrays were
performed on both SIV pol and R10 stimulated samples. To gauge
the gene expression of each animal in response to SIV pol
stimulation, gene expression data for each animal was calculated
as the ratio of its own R10 stimulated gene expression at the
concurrent time point. Thus, expression values reflect SIV pol-
specific transcriptional response.
Microarray data and functional analysis
Differential gene expression between the three groups was
determined using a Textbook one-way analysis of variance
(ANOVA) at the gene sequence level (ANOVA unadjusted
Figure 4. Viral load and CD4 counts in RMs after viral challenge. Viral load was measured at various time points in RMs challenged with 25
MID of SIVmac251. (A) Log viral load is presented for each animal in the Control, DNA, and DNA + RANTES groups. The average of viral loads for each
group is also displayed (bottom left). (B) Number of CD4+ T-cells in macaques following challenge as measured by flow cytometry and the average
number of CD4 T-cells/ml blood for each group is shown (bottom right).
doi:10.1371/journal.pone.0019681.g004
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groups; Rosetta Resolver, Rosetta Biosoftware). Pair-wise differ-
ences in expression between groups at each time point were
determined by a post-hoc test of the ANOVA results (Students-
Newman-Keuls adjustment, P#0.1).
Functional analysis of statistically significant gene expression
changes was performed using Ingenuity Pathway Analysis (IPA;
Ingenuity Systems), which analyzes gene expression data in the
context of known biological responses and regulatory networks.
Differentially expressed gene sequences were imported into IPA
software using the human GenBank accession numbers.
The biological functions and pathways that were most
significantly associated with the sets of gene sequences that were
differentially expressed between groups were assigned an enrich-
ment P-value adjusted for multiple testing with a Benjamini-
Hochberg test correction. For targeted assessment of specific
functions, the Fisher’s exact test was used to determine the
probability that each biological function assigned to that data set
was due to chance alone. Heatmaps for gene expression were
created using Spotfire DecisionSite 9.1.1. All gene expression data
described herearepubliclyavailableathttp://viromics.washington.
edu.
Assessment of CXCL9 and CXCL10
A set of PBMCs obtained 8 months post the last vaccination
were defrosted and stimulated in vitro with pol antigen for 24 h.
Supernatants were harvested and tested by ELISA (R and D
Systems, Minneapolis, MN) to determine the secretion of CXCL9
and CXCL10 protein.
MHC Class I genotyping
Comprehensive sequence based MHC-I genotyping was
performed using a combination of Sanger sequencing and
pyrosequencing methods as previously described [43,44]. Briefly,
total cellular RNA was isolated from PBMC using the MagNA
Pure LC RNA Isolation Kit (Roche Applied Sciences, Indianap-
olis, IN). cDNA was generated from RNA using the SuperscriptIII
First-Strand Synthesis System (Invitrogen, Carlsbad, CA) and used
as a template for PCR amplification with Phusion High-Fidelity
Polymerase (New England BioLabs, Ipswich, MA) and MHC-I
specific primers as described previously [43,44] PCR products
were gel purified using the MinElute Gel Extraction Kit (Qiagen,
Valencia, CA). For Sanger sequencing, these products were cloned
into bacteria using the Zero Blunt TOPO PCR Cloning Kit with
TOP10 Chemically Competent E. coli (Invitrogen, Carlsbad, CA).
96–192 transformed bacterial colonies per animal were grown
overnight in LB+50 ug/ml kanamycin; plasmid DNA was
subsequently isolated using the Perfectprep Plasmid 96 Vac Bind
Kit (5 PRIME, Gaithersburg, MD). Sanger sequencing reactions
covering the highly variable peptide-binding domain encoded by
MHC-I exons 2 & 3 were performed using sequence-specific PCR
primers described previously [44] with the DYEnamic ET
Table 2. MHC haplotype for rhesus macaques.
Group
Sanger
or 454
Typing
MHC Haplotype
Associated with
SIV Control Animal ID
Number of
Sequences
Evaluated
Number of
Unique MHC-I
Alleles
B*003
Lineage
B*017
Lineage
Control S N M4388 71 8
Control S N M4392 107 10
Control S N M4396 65 9
Control S N M4399 73 10
Control S N M4403 92 12
Control S N M4406 148 9
DNA S N M4387 44 7
DNA S N M4411 117 12
DNA S Y M4413 38 4 34.2
DNA 454 N M4416 1083 17
DNA S N M4421 110 6
DNA S N M4425 147 6
DNA+RANTES S Y M4408 100 12 31.0
DNA+RANTES S N M4410 126 11
DNA+RANTES S N M4415 96 11
DNA+RANTES S N M4417 68 6
DNA+RANTES S Y M4420 141 9 28.4
DNA+RANTES 454 Y M4424 780 21 12.1
Summary of comprehensive MHC class I genotypes of Chinese-origin rhesus macaques as determined by Sanger-based and Roche/454 pyrosequence-based typing.
MHC class I sequences from each animal were compared to an in-house database of all known Mamu sequences using BLASTN. Total numbers of sequences evaluated
and unique MHC-I alleles detected for each animal are listed. Pyrosequencing provided significantly greater depth of coverage, but the method used was still being
established at the time the genotyping was performed and as such, most animals were typed using Sanger-based methods. Animals observed with MHC-I alleles or
haplotypes associated with control of SIV replication (Mamu-B*003 and Mamu-B*017) are indicated by shading. The percentage of sequence reads corresponding to a
given protective allele lineage in each animal are shown in burgundy. Other alleles associated with control, such as the Indian-origin rhesus macaque alleles Mamu-
A1*001, Mamu-B*008 or Mamu-B*047, were not observed in this cohort. Only alleles with known positive association to SIV control are displayed here; there is always
the potential that positive associations to control will be identified for other alleles observed in this cohort in the future, since most alleles expressed by Chinese-origin
rhesus macaques have not been studied for correlations to SIV disease outcome.
doi:10.1371/journal.pone.0019681.t002
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PLoS ONE | www.plosone.org 8 June 2011 | Volume 6 | Issue 6 | e19681Terminator Cycle Sequencing Kit (GE Healthcare, Piscataway,
NJ), and analyzed using an Applied Biosystems 3730xl Genetic
Analyzer (Applied Biosystems, Foster City, CA). A subset of 5
animals was also genotyped using Roche/454-pyrosequencing of a
universal diagnostic 190 bp PCR amplicon in MHC-I exon 2.
This amplicon was amplified from cDNA, gel purified, quantified,
normalized, and pooled as previously described23 and run on a
Genome Sequencer FLX instrument at the 454 Sequencing
Center (454 Life Sciences, Branford, CT) or at the University of
Illinois at Urbana-Champaign High-Throughput Sequencing
Center (Urbana, IL). Sequence analysis was performed using
CodonCode aligner (CodonCode Corporation, Deham, MA) and
Lasergene 8 (DNA Star, Madison, WI). Assembled contigs were
compared to an in-house database of known rhesus macaque
MHC-I alleles using BLASTN.
Statistics
Two-tailed Mann-Whitney tests were performed using Prism
Graphpad Software to compare IFN-c ELISpots, T-cell prolifer-
ation, memory cell percent, and viral loads. P-values that were
,0.05 were considered a significantly different.
Results
Immunization induces robust SIV-specific responses
To evaluate the level of vaccine-induced immunity, we assessed
the IFN-c response to SIV gag, env, and pol by standard ELISpot
assay (Fig. 1). PBMCs were isolated two weeks after each
immunization and the cells were stimulated with pooled SIV gag,
env, and pol peptides. Ag-specific responses were augmented with
each subsequent immunization in the vaccinated groups, while little
or no response above background was detected in the naı ¨ve group.
Afterthefourthand finalimmunization,theaveragenumberofSIV
gag-specific IFN-c producing cells was similar between the two
immunized groups; 839 SFCs were detected in the DNA alone
group and 922 SFCs in the DNA+RANTES group. However, for
both SIV env- and pol-specific IFN-c responses, the DNA group
induced higher levels than in the DNA+RANTES group; env
responses averaged 6,872 and 2,631 SFCs per million PBMCs,
respectively, and pol responses were 8,867 and 5,825 SFCs,
respectively. Therefore, while DNA vaccination elicited robust
IFN-c responsesinbothgroupsofanimals,immune responsestothe
SIV env and pol Ags were greater in the DNA vaccine alone group
than in the RANTES-adjuvanted group.
Wenextinvestigated the ability of vaccine-induced SIV-specific T-
cells to proliferate upon antigen stimulation. PBMCs were isolated
from RMs four weeks after the fourth immunization, labeled with
CFSE, and then stimulated for 5 days with growth medium alone,
SIV peptides, or ConA. T-cell proliferation was measured by flow
cytometry, which showed that both CD4+ and CD8+ T-cell
proliferative responses were higher in the DNA alone group
compared to those from the DNA+RANTES group (Fig. 2). In
addition, higher average proliferative responses were observed in the
CD8+ compartment and that similar to ELISpot data, the env- and
pol-specific responses were more extensive than the gag-specific
response. These data show that DNA vaccination generates SIV-
specific immunity that is capable of proliferation upon restimulation
and that these responses were larger in animal receiving the DNA
vaccine alone than in those that were adjuvanted. Altogether, these
data demonstrate differences in the magnitudes of SIV-specific
immunity generated by immunization with the DNA vaccine alone
or in combination with the RANTES molecular adjuvant as
measured by standard immunological assays.
Since standard immunologicalassaysevaluatingAg-specificimmune
responses using ex vivo stimulation may be limiting, we expanded our
analysis of vaccine-induced immunity by examining the total level of
cellular activation following immunization in the absence of ex vivo
stimulation and primary cell culture. PBMC samples from before (Pre-
bleed) and after the fourth immunization (Post-imm.) were stained and
analyzed by flow cytometry to determine the overall change in total T-
cell activation after vaccination (Fig. 3). Since HLA-DR, major
histocompatibility complex class II cell surface receptor, molecules are
up-regulated on the surface of T-cells in response to signaling, we gated
HLA-DR+CD95+ T-cells to assess changes in T-cell activation after
vaccination (Fig. 3A). Increases in vaccine-induced activation for
CD4+ and CD8+ T-cells was determined for each animal by
subtracting basal activation levels during the Pre-bleed from levels
after the fourth immunization (Fig. 3B). Little increase in T-cell
activation was observed on average for the control group; average
activation levels for the control group were likely increased due to
animal M4399, which exhibited an increase in CD8+ T-cell activation
of almost 10% (data not shown) and may likely be the result of a
common infection. However, vaccination induced measurable increas-
es in the overall levels of CD4+ and CD8+T-cell activation in both the
DNA and the DNA+RANTES groups; vaccination with DNA alone
induced a significant (P,0.005) 3.7-fold increase in the average
percentage of CD8+ T-cell activation to a value of 10.4% while the
DNA+RANTES vaccine led to a 2.4-fold increase in activation to a
value of 6.8%.However,no significant increase in the levelof CD4+T-
cell activation was observed in either vaccinated group. When the
phenotype of activated T-cells was investigated by staining with CD28
and CD45RA, which differentiates naı ¨ve (CD28+CD45RA+), effec-
tors/terminally differentiated effectors (CD282CD45RA+), central
memory (CD28+CD45RA2) and effector memory (CD28
2CD45RA2), the DNA+RANTES vaccinated animals were ob-
served to have greater percentages of activated central memory CD8+
T-cells on average (1.9-fold higher), but lower percentages of effector
memory cells (1.3-fold lower) when compared with DNA vaccinated
RMs (Fig. 3C). While no significant difference in CD4+ central
memory or effectors between the vaccinated groups was found, there
was a 2.2-fold higher percentage of effector memory cells in the
DNA-vaccinated animals on average (data not shown). Altogether,
these data show that vaccination induced measurable amounts of
activation in the T-cell compartment when estimated longitudinally in
the absence of ex vivo stimulation, but that inclusion of the RANTES
adjuvant during vaccination shifted the activation phenotype of
memory cells from effector to the central memory subset. Therefore,
while DNA vaccination alone induced a greater amount of SIV-
specific effectors as measured by standard immunological assays, DNA
vaccinationadjuvanted byRANTES generated a greaterpercentage of
central memory CD8+ T-cells capable of an activated phenotype
following the final immunization.
Figure 5. Vaccination corresponded to differential gene expression response to SIV Pol stimulation. (A) 563 gene sequences were
differentially expressed at 8 months post-vaccination by ANOVA while (B) 699 gene sequences were differentially expressed among the three
treatment groups at 10 days post-challenge by ANOVA. Genes shown in red have higher expression than their genetically matched mock, while
genes shown in green have lower expression. Clustering was by Hierarchical algorithm with average link criteria and cosine similarity measure. Color
saturation was set at +/20.6 logratio to mock.
doi:10.1371/journal.pone.0019681.g005
Gene Signatures of SIV DNA Immunized Macaques
PLoS ONE | www.plosone.org 9 June 2011 | Volume 6 | Issue 6 | e19681Gene Signatures of SIV DNA Immunized Macaques
PLoS ONE | www.plosone.org 10 June 2011 | Volume 6 | Issue 6 | e19681DNA immunization with RANTES correlates with control
of SIV replication following challenge
Animals were challenged eight months following the fourth
immunization with 25 monkey infectious doses (MID) of
SIVmac251 by the intrarectal route. The average viral load in
the control group at 2 weeks after challenge (peak viral load) was
7.4 logs (Fig. 4A). The average peak viral load of the DNA group
and the DNA+RANTES group was 6.3 logs and 6.1 logs,
respectively, and both were significantly lower than the viral load
the control group (P=0.007 and P=0.01). However, the viral
loads in DNA+RANTES group remained significantly lower than
the control group at all time points measured following the peak of
viremia (P,0.05). In addition, the animals that received
DNA+RANTES exhibited a significantly lower viral load at day
84 and 112 as compared with the DNA group (P,0.05).
Previous SIV challenge studies have identified several MHC-I
alleles that are associated with natural control of viral replication
[45–49]. To evaluate the potential contribution of host MHC-I
genetics in this study, we performed comprehensive sequence-
based typing of all of the animals retrospectively (Table 2). Post-
hoc analysis revealed that there were four animals that expressed
the protective Mamu-B*003 allele, two in the DNA+RANTES
group and one in the DNA group. An animal in the
DNA+RANTES group was found to have a class I allele of the
Mamu-B*017 lineage. Although we did observe significantly lower
viral loads in the animals with protective haplotypes at the end of
the study (p=0.033), there was no statistical difference in peak
(p=0.968) and set point (p=0.161) viral loads. Thus, these
protective alleles may have contributed to control of viral
replication during chronic infection, but they do not appear to
correlate with a vaccine effect on control of viral replication
observed early after infection.
Since depletion of CD4
+ T-cells from mucosal sites and blood is
a hallmark of HIV and SIV infection [50–53], we tested the CD4
T-cell counts in the blood of RMs after challenge. The CD4
+ T-
cell count relative to week 0 after challenge in the control group
was lower than that in the DNA group and DNA+RANTES
group (Fig. 4B). There was not a significant difference between
them. Altogether, these data show that despite lower numbers of
SIV-specific effectors following vaccination as measured by
standard immunological assays, the DNA+RANTES immunized
animals exhibiting greater levels of SIV-specific central memory
cells controlled virus better than the DNA alone group and had
higher CD4 T-cell counts.
Vaccination is associated with differential transcriptional
response to Pol stimulation in PBMCs
To explore the long-term effect of vaccination on response to
SIV antigen stimulation and possible mechanisms underlying
differential response to SIV challenge, gene expression in response
to SIV pol peptide stimulation in fresh PBMCs was measured
using DNA microarray at eight months following the last
vaccination (prior to SIV challenge) and at peak viremia (10 days
following SIV challenge). We applied statistical methods to
distinguish treatment groups (n=5–6 animals per group) by gene
expression. At eight months following vaccination, there were 563
gene sequences that distinguished the three groups and at peak
viremia there were 699 gene sequences that distinguished the three
groups (Figure 5). The majority of gene expression differences
were between the control group and any of the vaccinated groups,
with quantitatively fewer differences distinguishing the vaccine
groups. These general gene expression signatures mirror the
standard immunological assays, suggesting not only the long-term
impact on antigen specific response to vaccination but also relative
subtly in the differences between the vaccinated groups.
Vaccination results in an enhancement of TH1 response
to stimulation at 8 months post-vaccination that is
maintained following SIV challenge
From these two ANOVA sets, 124 gene sequences distinguished
the treatment groups at both time points. The biological functions
of the genes that distinguish the treatment groups at days 0 and 10
were explored using the Ingenuity Analysis Suite (IPA). Among
the genes that distinguish the groups, there was a significant
enrichment of genes with functions related to both cellular and
innate immune response (Table S1). Further analysis suggested
that vaccination was associated with an enhanced Th1 response to
pol stimulation at both pre- and post-challenge which included the
increase in the expression of genes with roles in Interferon
response, antigen presentation and chemokines (CXCL9, 10, 11)
that activate and mobilize T-cells (Figure 6). This enhancement of
interferon-related transcriptional response correlated to the
increase in the number of IFN- c producing cells as determined
by the ELISpot response observed in vaccinated animals at pre-
and post-challenge.
Vaccination induces Ag-specific cells capable of secreting
chemokines CXCL9 and CXCL10
To examine if differences in chemotactic gene expression
correlated with an increase in protein expression, a separate set of
PBMCs from 8 months after the last immunization were defrosted
and stimulated in vitro with SIVpol antigen for 24 h. Supernatants
were harvested and CXCL9 and CXCL10 proteins were measured
by ELISA. We observed an average of 1,000 pg/ml and 1,100 pg/
ml of CXCL10 for the DNA and the DNA+RANTES groups,
respectively (Figure 7). The expression of CXCL9 protein was
notably lower and less consistently detected in the PBMC of the
vaccinated animals. Three of the 6 animals had responses above
background in the DNA group whereas 1 of 6 animals had levels
detectable above background in the DNA+RANTES group. In
addition, we tested CXCR3, the receptor for CXCL9 and CXCL10
and found that the cells secreting IFN- c were predominantly
CXCR3 positive. However, when we stained for granzymeB and
Tbet these CXCR3+ cells were not positive (data not shown).
Vaccination results in an augmented cytolytic
transcriptional response at 8 months post-vaccination
but not at peak viremia
Next, we examined the biological functions of the genes that
distinguishedthetreatmentgroupsonlyat8monthspost-vaccination
(Table S2). Differences in the expression of these genes suggest a
Figure 6. Increased expression of genes regulating IFN, Ag presentation, and chemotactic response following vaccination. (A) IPA
network indicating the relationship between these differentially expressed genes. Chemokine- and cytokine-related genes (pink), IFN and anti-viral
genes (blue), and genes related to protein-ubiquination and Ag presentation (purple) are shown. (B) Heatmap representing the Pol-antigen
stimulated gene expression for each animal at 8 months post-vaccination (m.p.v.) and 10 days post-challenge (d.p.c.). Genes in red have higher
expression than their genetically matched mock and genes in green have lower expression. Clustering was by Hierarchial algorithm with average link
criteria and cosine similarity measure. Color saturation was set at +/21.0 logratio to mock.
doi:10.1371/journal.pone.0019681.g006
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following vaccination that were not maintained at peak viremia. We
found that vaccination was associated with an up-regulation of
cytolysis-related gene expression following POL stimulation
(Figure 8). A qualitative examination of the expression of these
genes at 10 days post-challenge suggested that these genes did not
pass the statistical thresholds at peak viremia because the expression
of these genes was generally up-regulated in all three groups at peak
viremia (Data not shown).
Vaccination is associated with a decrease in cell death-
related response at peak viremia
We next examined the genes that distinguished the groups only
at peak viremia (Table S3). Differences in the expression of these
genes reflect long-term reprogramming of response to SIVpol
which is evident concurrent with the vast immunological insult of
SIV challenge. Interestingly, at peak viremia, vaccination was
associated with a decrease in the expression of cell death-related
genes following SIVpol-stimulation (Figure 9).
Adminstration of RANTES adjuvant with vaccination
results in specific reprogramming of transcriptional
response to SIVpol
The DNA+RANTES group exhibited the greatest suppression
of SIV viral load during the chronic phase of infection in this
study. We next examined the genes that were uniquely expressed
in the DNA+RANTES group to see if differences in transcrip-
tional response could be correlated to the differential response to
SIV challenge. Using a Student’s post-hoc comparison (P,0.1) on
the gene expression ANOVA results, we found that 156 gene
sequences distinguished the DNA+RANTES group from both the
DNA and Control group at 8 months post-vaccination and 159
gene sequences distinguished the RANTES group from the other
two groups at peak viremia. Although there was minimal overlap
between the two gene sets, the top functions related to RANTES-
specific expression were very similar at both pre- and post-SIV
challenge. Genes with RANTES-specific expression held functions
related cell death, growth, inflammation and movement (Table S4,
Figure 10). It is interesting to note that these changes in gene
expression in the DNA+RANTES group not only reflect a
sustained reprogramming of response to SIVpol that is unique, but
these would not have necessarily been predicted by the concurrent
immunological assays. Although differences in expression, such as
differential expression of proliferation genes, were not born out in
the immunological assays at the time, these altered responses may
have as yet undetermined impact on immunological response that
allows these animals to sustain their CD4 counts and suppress SIV
to a greater extent during chronic infection.
Discussion
Improved protection is the most important goal in the
development of an effective vaccine for HIV-1. All of the
vaccinated animals in the current study acquired SIV following
a high-dose challenge with SIVmac251. However, we observed
that animals in both vaccinated groups experienced a significant
long-term alteration in their immune response to SIV Ags and
were able to suppress viral load at peak viremia and during
chronic infection. These alterations in immunity were accompa-
nied by an increase in cellular immunity to SIV. In particular, we
observed the induction of IFN-c producing effector cells and an
increase in the expression of interferon signaling pathway genes in
vaccinated animals. An increase in the stimulated expression of
genes related to chemotaxis including CXCL9, CXCL10 and
CXCL11 were also observed. Subsequent analysis of protein levels
of CXCL9 and CXCL10 secreted from Ag-activated PBMCs
corroborated the microarray analysis (Figures 6b and 7). Given
this data we investigated CXCR3, the receptor for CXCL9,
CXCL10 and CXCL11. We found that the cells secreting IFN- c
were predominantly CXCR3 positive (Figure 7). These significant
alterations in interferon, proliferation, and chemotactic responses
Figure 7. CXCL9 and CXCL10 proteins were measured by
ELISA. PBMC isolated at 8 months after last immunization were
defrosted and stimulated in vitro with SIVpol peptide for 24 h. (A)
Supernatants were harvested and measured by ELISA for CXCL9 and
CXCL10 proteins. (B) The level of CXCR3 was assessed using antibodies
specific for CXCR3, CCR7, CD4, CD8, and CD4. PBMCs were from same
time point.
doi:10.1371/journal.pone.0019681.g007
Gene Signatures of SIV DNA Immunized Macaques
PLoS ONE | www.plosone.org 12 June 2011 | Volume 6 | Issue 6 | e19681Figure 8. Vaccination is associated with differential regulation of cell lysis pathways at 8 months post-vaccination. (A) IPA networks
indicate the relationship between differentially expressed genes related to cytolysis from analysis of the genes that significantly distinguished the
treatment groups only at peak viremia by ANOVA. Molecule shading reflects the average logratio of expression for each group. Red represents an
average increase in expression, green represents a decrease in average expression. (B) Heatmap indicating the expression of cytolysis genes at 8
months post-vaccination. Genes shown in red have higher expression than their genetically matched mock, gene shown in green have lower
expression than their genetically matched mock. Clustering was by Hierarchial algorithm with average link criteria and cosine similarity measure.
Color saturation was set at +/20.4 logratio to mock.
doi:10.1371/journal.pone.0019681.g008
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viremia. However, the vaccine groups did not respond equally to
challenge which suggests that adjuvanting altered the immune
response to challenge.
RANTES co-immunization reduced viral load following
challenge to a greater extent than DNA vaccination alone.
However, a direct correlation between a strong immune response
to SIV peptides as measured by standard immunological assays
and suppression of SIV viral load was not observed. Previous
studies have demonstrated that RANTES, used as an adjuvant to
DNA or other vaccines, could enhance Ag-specific T-cell mediated
protective immunity against HSV [54] and SHIV [55]. In
contrast, we observed that the co-injection of RANTES with the
vaccine actually decreased immune responses to SIV peptides
when compared to those in animals receiving the DNA vaccine
alone. Therefore, it is obvious from this study that others factors
including the quality and/or phenotype of vaccine-specific
immunity may be more important than magnitude alone.
Of particular interest was the upreglation of IL-27. IL-27 is
implicated in the balance between the induction of CD8+ T cell
function and Th17 helper cells. IL-27 is a heterodimeric cytokine
belonging to a family of structurally related ligands that also
includes IL-12, IL-23 and IL-6. Batten et al demonstrated that IL-
27alpha deficient mice were hyper-susceptible to EAE and
generated more IL-17 producing T helper cells [56]. IL-27 acted
directly to suppress the development of IL17 producing effector T
helper cells. And, recently Gosselin et al [57] found that it is the
CD4+CCR6+ sub-population of T cells that are infected by HIV-
1 in humans. The authors describe these lymphocyte sub-
populationas as Th17 and Th1Th17 cells. Furthermore Cecchi-
nato [58] illustrated that the Th17 cells in the gut are depleted first
following SIVmac251 challenge. Finally, macaques that are
capable of controlling infection have preserved Th17 cells. It is
interesting that post infection, perhaps upon viral pathogenesis we
no longer see and increase in IL-27 gene expression.
Indeed, flow-based activation analysis demonstrated a signifi-
cantly greater percentage of vaccine-induced central memory
CD8+ T-cells capable of an activated phenotype (Fig. 3) which
may account for increased virus suppression upon challenge in
these animals. Surface staining of lymphocyte activation without ex
vivo stimulation showed that vaccination induced measurable
amounts of activation in the T cell compartment in both vaccine
groups. However, the inclusion of the RANTES adjuvant shifted
the activation phenotype of memory cells from effector to the
central memory subset. This indicated that, while DNA vaccina-
tion alone induced a greater amount of SIV-specific effectors,
DNA vaccination adjuvanted by RANTES generated a greater
percentage of central memory CD8+ T cells capable of an
activated phenotype following the final immunization. According
to the model proposed by Lanzavecchia A et al, [59], protective
memory is mediated by effector memory T cells (TEM) that
migrate to inflamed peripheral tissues and display immediate
effector function, whereas reactive memory is mediated by central
memory T cells (TCM) that home to T cell areas of secondary
lymphoid organs, have little or no effector function, but readily
proliferate and differentiate to effector cells in response to
antigenic stimulation. This again suggests that the antigen-specific
lymphocytes induced by the co-injection of RANTES were more
likely to migrate to the lymph nodes as site of viral replication.
Therefore, it is clear that memory T-cell quality was more
important than quantity in providing protection.
In further support of this premise, we observed that genes
related to immune cell trafficking, DNA repair, and regulation of
transcription had expression patterns in the DNA+RANTES
group which distinguished them from the control and DNA only
groups. Of particular interest was the trafficking pathway; CD69,
an early leukocyte activation molecule, was up-regulated to a
greater extent in the RANTES-adjuvanted group than in the
DNA-vaccinated group. This molecule is an early inducible cell
surface glycoprotein acquired during lymphoid activation that is
involved in lymphocyte proliferation and functions as a signal-
transmitting receptor in lymphocytes and natural killer cells.
Shiow et al [60] demonstrated that CD69 functions downstream of
IFN-alpha and -beta and possibly other activating stimuli to
promote lymphocyte retention in lymphoid organs. The function
of the lymphoid organs is to filter-out invading pathogens and
present them to immune cells, the high levels of viremia seen
following primary HIV-SIV infection most probably lead to an
efficient infection of the lymphoid tissue. Once virus is trapped
within the germinal centers of the lymphoid organs, cellular
recruitment and activation occur as part of the normal immune
response. It is possible that the lower immune response we are
seeing in the periphery is a result of the RANTES-induced antigen
presenting cells trafficking to the lymphoid organ more efficiently
than in the DNA alone vaccine. This is also supported by data
showing that the group of macaques that were co-injected with
RANTES had lower numbers of these Ag-specific PBMC cells in
the periphery. It is possible that the lower levels of immune cells
observed in the periphery is a result of a relocation of the cells
responsible for viral suppression to the sites of infection.
The robust and sustained response to SIV antigens in the DNA
and DNA+RANTES groups reflects the long-term efficacy of the
DNA vaccine regimen presented here. This shows that the use of
highly optimized expression vectors concurrently with EP delivery
can induce a robust immune response that is qualitatively different
from its DNA alone counterpart. Specifically, the co-delivery of
RANTES can change the profile of the immune response so that
SIV load is decreased in the peripheral blood. Although direct
evidence of RANTES-induced protection against HIV or SIV has
yet to be demonstrated, Hadida et al. have previously shown that it
enhances the HIV-specific cytotoxicity of CD8+ T-cells [61].
Furthermore, they suggested that RANTES-induced FasL expres-
sion could be a defense mechanism leading to the elimination of
HIV-infected cells. Therefore, FasL is likely to function in concert
with the HIV-suppressive activity of RANTES to block CCR5 and
induce apoptosis. However, the precise relationship between
RANTES and FasL for HIV-suppression is not fully understood
as enhanced expression of FasL in CTLs may also contribute to
pathogenesis by accelerating the decline of Fas-expressing CD4+
or CD8+ cells [62],While our data suggest that this might be due
in part to differences in immune cell localization following
challenge, further studies are needed to assess whether DNA
vaccination combined with RANTES adjuvanting leads to a shift
in immune cell populations and viral load at sites of active
infection. Overall, this study illustrates the utility of nonstandard
immunological assays including flow-based activation analysis and
Figure 9. Vaccination is associated with decrease in the expression of cell death related networks at peak viremia. IPA network
indicate the relationship between differentially expressed genes related to cell death as determined from analysis of the 539 genes that significantly
distinguished the treatment groups only at peak viremia by ANOVA. Molecule shading reflects the average log-ratio of expression for (A) Control, (B)
DNA, and (C) DNA+RANTES groups at ten days post-SIV challenge. Red represents an average increase in expression and green represents a decrease.
doi:10.1371/journal.pone.0019681.g009
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PLoS ONE | www.plosone.org 15 June 2011 | Volume 6 | Issue 6 | e19681Figure 10. Expression for genes with unique expression in the DNA+RANTES group. (A) Expression of 156 gene sequences distinguished
the DNA+RANTES group from both the DNA only and Control group at 8 months post-vaccination. (B) Expression of 159 gene sequences
distinguished the DNA+RANTES group from both the DNA only and Control group at 10 days post-challenge. Genes shown in red have higher
expression than their genetically matched mock, gene shown in green have lower expression than their genetically matched mock. Clustering was by
Hierarchial algorithm with average link criteria and cosine similarity measure. Color saturation was set at +/20.6 logratio to mock.
doi:10.1371/journal.pone.0019681.g010
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novel mechanisms of protection that would have been otherwise
overlooked by standard assays.
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